Back to Authors

Demark-Wahnefried, Wendy

0000-0001-5241-932X

Mayo Clinic

O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Citations 12

Disease drivers of aging
Hodes, Richard J. , Sierra, Felipe , Austad, Steven N. , Epel, Elissa S. , Schafer, Marissa , LeBrasseur, Nathan K. , Wiley, Christopher D. , Campisi, Judith , Sehl, Mary E. , Scalia, Rosario , Eguchi, Satoru , Kasinath, Balakuntalam S. , Halter, Jeffrey B., Cohen, Harvey Jay, Demark‐Wahnefried, Wendy , Ahles, Tim A. , Barzilai, Nir , Hurria, Arti , Hunt, Peter W. , Schafer, Marissa J, Neigh, Gretchen N. , Erlandson, Kristine M. , LeBrasseur, Nathan K , Schafer, Marissa J , Demark-Wahnefried, Wendy

Annals of the New York Academy of Sciences | December 14, 2016 | Volume: 1386 | Issue: 1 | Pages: 45-68

10.1111/nyas.13299 Get It

It has long been known that aging, at both the cellular and organismal levels, contributes to the development and progression of the pathology of many chronic diseases. However, much less research has examined the inverse relationship—the contribution of chronic diseases and their treatments to the progression of aging‐related phenotypes. Here, we discuss the impact of three chronic diseases (cancer, HIV/AIDS, and diabetes) and their treatments on aging, putative mechanisms by which these effects are mediated, and the open questions and future research directions required to understand the relationships between these diseases and aging.
Conducting Cancer Control and Survivorship Research via Cooperative Groups: A Report from the American Society of Preventive Oncology
Demark‐Wahnefried, Wendy , Mustian, Karen M. , Minasian, Lori M. , Rowland, Julia, Sprod, Lisa K., Janelsins, Michelle C. , Peppone, Luke J. , Sloan, Jeff A. , Engquist, Karen Basen, Palesh, Oxana Gronskaya , Jones, Lee W. , Buist, Diana S.M. , Paskett, Electra D. , Demark-Wahnefried, Wendy

Cancer Epidemiology, Biomarkers & Prevention | May 5, 2011 | Volume: 20 | Issue: 5 | Pages: 1050-1055

10.1158/1055-9965.epi-11-0176 Get It

Abstract As the number of cancer survivors expands, the need for cancer control and survivorship research becomes increasingly important. The National Cancer Institute (NCI) Cooperative Groups may offer a viable platform to perform such research. Observational, preventive, and behavioral research can often be performed within the cooperative group setting, especially if resources needed for evaluation are fairly simple, if protocols are easily implemented within the typical clinical setting, and if interventions are well standardized. Some protocols are better suited to cooperative groups than are others, and there are advantages and disadvantages to conducting survivorship research within the cooperative group setting. Behavioral researchers currently involved in cooperative groups, as well as program staff within the NCI, can serve as sources of information for those wishing to pursue symptom management and survivorship studies within the clinical trial setting. The structure of the cooperative groups is currently changing, but going forward, survivorship is bound to be a topic of interest and one that perhaps may be more easily addressed using the proposed more centralized structure. Cancer Epidemiol Biomarkers Prev; 20(5); 1050–5. ©2011 AACR.